Medicine
Pemetrexed disodium hemipentahydrate 100 mg/4.2 mL powder for injection
Pemetrexed disodium hemipentahydrate 100 mg/4.2 mL powder for injection is a generic prescription medicine for intravenous use, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store powder at 25°C (77°F), excursions permitted between 15° and 30°C (59°…
Key facts
- Active ingredient (INN)
- Pemetrexed disodium hemipentahydrate
- Brand
- Sold under the generic name
- Strength
- 100 mg/4.2 mL
- Dosage form
- Powder for injection
- Route
- Intravenous
- Packs
- 1 vial
- Manufacturer
- Sagent Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store powder at 25°C (77°F), excursions permitted between 15° and 30°C (59° and 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 15 December 2024
- Identifiers
- RxCUI 1728072, 1728077DailyMed set ID fa8f1f52-3f05-4ae8-bfec-7f0a029e6825NDC 25021-260Application ANDA204890
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial in 1 carton / 4.2 mL in 1 vial | 25021-260-10 | Sagent Pharmaceuticals | 15 December 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Pemetrexed disodium hemipentahydrate
Clinical summary
Pemetrexed disodium hemipentahydrate is a folate analog metabolic inhibitor indicated in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), among other approved uses. MedsAcross supplies Pemetrexed disodium hemipentahydrate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Pemetrexed disodium hemipentahydrateFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- PEMRYDI RTU prescribing information (Amneal Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Pemetrexed disodium hemipentahydrate 100 mg/4.2 mL powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.